IJCS | Volume 32, Nº2, May/June 2019

301 1. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, et al. A Risk score to predict bleeding in patients with acute coronary syndromes J Am Coll Cardiol. 2010;55(23):2556-66. 2. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guideline on myocardial revascularization: The Task Force on myocardial revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery developed with the special contribution of the European Association of percutaneous cardiovascular interventions. Eur Heart J. 2014;35(37):2541-619. 3. Nagai K, Hayashi K, Yasui T, Katanoda K, IsoH, Kiyohara Y, et al. Disease history and risk of comorbidity in women’s life course: a comprehensive analysis of the Japan Nurses’ Health Study baseline survey. BMJ Open 2015;5(3):e0006360 4. Jensen CJ, Naber CK, Urban P, Onq PJ, Valdes-Chavarri M, Abizaid AA, et al. Two-Year Outcomes of High Bleeding Risk Patients After Polymer- Free Drug-Coated Stents: a LEADERS FREE substudy. EuroIntervention 2018;13(16):1946-9. 5. Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, et al. Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in “Real-World” Practice : 18-Month Clinical and 9-MonthAngiographic Outcomes. JACC Cardiovasc Interv. 2009(4):303-9. 6. Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary inter- vention: implications for contemporary practice. J Am Coll Cardiol. 2009;53(22):2019-27. 7. Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation. 2007;116(24):2793–801. 8. Wang TY, Xiao L, Alexander KP, Rao SV, Kosiborod MN, Rumsfeld JS, et al. Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation. 2008;118(21):2139-45. 9. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, et al. The relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292(13):1555–62. 10. SabatineMS, MorrowDA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111(16):2042–9. 11. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline risk of major bleeding in non–ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/ AHA Guidelines) bleeding score. Circulation. 2009;119(14):1873–82. 12. Najm HK, Leddy D, Hendry PJ, Marquis JF, Richardson D, Keon WJ. Postoperative symptomatic internal thoracic artery stenosis and successful treatment with PTCA. Ann Thorac Surg 1995;59(2):323– 7. 13. Marx R, Klein RM, Horlitz M, Ketteler T, Schannwell CM, Lapp H, et al. Angioplasty of the internal thoracic artery bypass-graft an alternative to reoperation. Int J Cardiol.2004;94(2-3):143-9. 14. Stewart EA, Barbieri RL, Falk S. Overview of treatment of uterine leiomyomas(fibrosis). [Internet]. [Cited in 2018 Jan 30]. Available from: https://www.uptodate.com/contents/overview-of-treatment-of- uterine-leiomyomas-fibrosis References Falcão et al. Coronary angioplasty with bleeding Int J Cardiovasc Sci. 2019;32(3)297-301 Case Report This is an open-access article distributed under the terms of the Creative Commons Attribution License